Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/60—Salicylic acid; Derivatives thereof
  • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
  • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
  • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
  • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/18—Sulfonamides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring

Definitions

• the present invention relates to novel salicylic acid derivative compound, compositions containing same and methods inhibiting STAT3 activity or for treating cancer where STAT3/5 are involved, such as in brain, breast, colon, hematologic, lung, ovarian and prostate cancers using said compounds.
• BACKGROUND OF THE DISCLOSURE STAT3 is persistently activated in over a dozen types of human cancers, including all the major carcinomas, including breast, brain, colon, pancreas, ovarian, and squamous cell carcinomas of head and neck (SCCHN) cancers, and melanomas as well as some hematologic tumors (Bowman T, et al (2000) Oncogene 19, 2474-88, and Darnell, J. E. (2005) Nat. Med. 1 1, 595-596).
• SCCHN head and neck
• GBM Glioblastoma
• STAT proteins were originally discovered as latent cytoplasmic transcription factors that mediate cytokine and growth factor responses (Darnell, J. E., Jr. (1996) Recent Prog. Norm. Res. 51, 391-403; Darnell, J. E. (2005) Nat. Med. 1 1, 595-596). Seven members of the family, STAT1, STAT2, STAT3, STAT4, STAT5a and STAT5b, and STAT6, mediate several physiological effects including growth and differentiation, survival, development and inflammation. STATs are SH2 domain-containing proteins.
• STATs Upon ligand binding to cytokine or growth factor receptors, STATs become phosphorylated on critical Tyr residue (Tyr705 for STAT3) by growth factor receptors, cytoplasmic Janus kinases (Jaks) or Src family kinases. Two phosphorylated and activated STAT monomers dimerize through reciprocal pTyr-SH2 domain interactions, translocate to the nucleus, and bind to specific DNA-response elements of target genes, thereby inducing gene transcription (Darnell, J. E., Jr. (1996) Recent Prog. Norm. Res. 51, 391-403; Darnell, J. E. (2005) Nat. Med. 1 1, 595-596).
• STAT3 protein is one of seven family members of the STAT family of transcription factor proteins.
• STAT3 is activated through phosphorylation of a tyrosine 705 (Y705) that initiates complexation of two phosphorylated STAT3 monomers (pSTAT3).
• pSTAT3 homo dimers are mediated through reciprocal STAT3 Src Homology 2 (SH2) domain-pY705 STAT3 interactions.
• pSTAT3:pSTAT3 homodimers translocate to the nucleus and bind DNA, promoting STAT3 target gene transcription.
• Targeting STAT3 has been previously achieved with dominant negative constructs, oligonucleotides or, most commonly, phosphopeptidic agents that mimic the native pY705 containing binding sequence.
• STAT3 inhibitors were designed for treatment of cancers harboring hyperactivated STAT3 protein.
• Acid-based inhibitors have been identified in WO2012/018868 that potently and selectively block STAT3 dimerization and DNA-binding activity, namely, compound 450, also referred to as BP-1-102 (sometimes referred to as compound 1 herein).
• Compound 450 in WO2012018868 potently suppresses multiple oncogenic properties in diverse cultured cancer cells (breast, lung, pancreatic, prostate, lung), including: cell proliferation, anchorage-independent cell growth, migration, invasion and motility.
• STAT3 It is selective for STAT3, with over 10-fold less binding to 93% homologous STAT protein, STAT1. It showed little or no effect on phosphorylation of She, Src, Jak-1/2, Erkl/2 or Akt and had no effect on non-transformed cells (NIH 3T3 cells, STAT3 null mouse embryo fibroblasts, or mouse thymus stromal cells, nor does it affect transformed cells that do not harbor activated STAT3). Moreover, BP-1-102 exhibited striking anti-tumor effects in vivo in murine xenograft models of lung or breast cancer resulting in dramatic regression in tumor volumes.
• STAT3 inhibition induces cancer cell death and tumor regression.
• Small-molecule STAT3 inhibitors thus provide tools for probing the molecular dynamics of the cellular processing of STAT3 to understand STAT3's role as a signaling intermediate and a molecular mediator of the events leading to carcinogenesis and malignant progression.
• the STAT3 pathway is a key oncogenic driver in over a dozen types of human cancers, including all the major carcinomas, including breast, brain, colon, pancreas, ovarian, and squamous cell carcinomas of head and neck (SCCHN) cancers, and melanomas as well as some hematologic tumors (Bowman T, et al (2000) Oncogene 19, 2474-88, and Darnell, J. E. (2005) Nat. Med. 1 1, 595-596) the direct inhibition of STAT3 would provide a molecularly targeted route for effectively managing these cancers and especially aggressive forms such as GBM.
• SCCHN head and neck
• STAT5 signaling like STAT3 signaling, is transiently activated in normal cells and is deactivated by a number of different cytosolic and nuclear regulators, including phosphatases, SOCS, PIAS, and proteasomal degradation. Like STAT3, STAT5 has gained notoriety for its aberrant role in human cancers and tumorigenesis, having been found to be constitutively activated in many cancers, including those of the breast, liver, prostate, blood, skin, head and neck. (Muller, J., et al. ChemBioChem 2008, 9, 723-727). In cancer cells, STAT5 is routinely constitutively phosphorylated which leads to the aberrant expression of STAT5 target genes resulting in malignant transformation.
• STAT5 has been identified as a key regulator in the development and progression of acute myelogenic (AML) and acute lymphoblastic leukemias (ALL; Gouilleux-Gruart, V., et al. Leukemia and Lymphoma 1997, 28, 83-88; Gouilleux-Gruart, V., et al. Blood 1996, 87, 1692-1697; Weber-Nordt, R. M., et al.
• AML acute myelogenic
• ALL acute lymphoblastic leukemias
• inhibitors of upstream STAT5 activators have been shown to exhibit promising anti-cancer properties (Pardanani, A., et al. Leukemia 2011, 25, 218-225; Quintas-Cardama, A., et al. Nature Reviews Drug Discovery 2011, 10, 127- 140).
• the invention in one aspect, relates to compounds useful as inhibitors of STAT3.
• the disclosed compounds and products of disclosed methods of making, or a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof are modulators of STAT3 and/or STAT5 activity, methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with a STAT3 activity dysfunction using same.
• the present invention relates to compounds that bind to STAT5 protein and negatively modulate STAT5 activity.
• compositions comprising a therapeutically effective amount of a disclosed compound and a pharmaceutically acceptable carrier.
• Disclosed are methods for the treatment of a disorder associated with STAT3/STAT5 activity dysfunction, preferably hyperactivity or over-expression, in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a disclosed compound, or a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof.
• Also disclosed are methods for inhibition of STAT3 and/or STAT5 activity in a mammal comprising the step of administering to the mammal a therapeutically effective amount of least one disclosed compound, or a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof.
• Also disclosed are methods for inhibiting STAT3 and/or STAT5 activity in at least one cell comprising the step of contacting the at least one cell with an effective amount of least one disclosed compound, or a pharmaceutically acceptable salt, hydrate, solvate, or polymorph thereof.
• R is different from Ri and both R and Ri are selected from the group consisting of :
• R 2 is a benzyl substituted with 1-5 halogens, preferably -Cl-F or -Br, and
• R 3 is selected from the group consisting of H or OH.
• the invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a disclosed compound, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
• a pharmaceutical composition comprising a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof, and an acceptable excipient.
• a method for inhibiting STAT3 and/or STAT5 activity comprising administering a therapeutically effective amount of a compound as defined herein or a pharmaceutically acceptable salt, solvate or hydrate thereof, to a patient.
• a method for treating or preventing cancer associated with STAT3/STAT5 activity dysfunction comprising administering a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt, solvate or hydrate thereof, to a patient.
• the cancer is from solid or hematological tumors.
• the cancer is one harbouring activated STAT3 and/or STAT5.
• Such cancer can be for example breast, liver, prostate, blood, skin, head, neck cancer, glioblastoma or acute myelogenic (AML) and acute lymphoblastic leukemias.
• a compound as defined herein or a pharmaceutically acceptable salt, solvate or hydrate thereof in the manufacture of a medicament for treating or preventing cancer harbouring activated STAT3 and/or STAT5, such as cancer from solid or hematological tumors, breast cancer, liver cancer, prostate cancer, blood cancer, skin cancer, head cancer, neck cancer, glioblastoma or acute myelogenic (AML) and acute lymphoblastic leukemias.
• activated STAT3 and/or STAT5 such as cancer from solid or hematological tumors, breast cancer, liver cancer, prostate cancer, blood cancer, skin cancer, head cancer, neck cancer, glioblastoma or acute myelogenic (AML) and acute lymphoblastic leukemias.
• composition as defined herein for use in inhibiting STAT3 and/or STAT5 activity.
• activated STAT3 and/or STAT5 such as the cancer is from solid or hematological tumors, breast cancer, liver cancer, prostate cancer, blood cancer, skin cancer, head cancer, neck cancer, glioblastoma or acute myelogenic (AML) and acute lymphoblastic leukemias.
• Also disclosed are methods for manufacturing a medicament comprising combining at least one disclosed compound or at least one disclosed product with a pharmaceutically acceptable carrier or diluent.
• the invention relates to the use of a disclosed compound in the manufacture of a medicament for the treatment of a disorder associated with STAT3/STAT5 activity dysfunction (such as hyperactivity or over-expression).
• the invention relates to the use of the disclosed compound in the manufacture of a medicament for the treatment of a cancer harbouring activated STAT3 and/or STAT5, such as the cancer is from solid or hematological tumors, breast cancer, liver cancer, prostate cancer, blood cancer, skin cancer, head cancer, neck cancer, glioblastoma or acute myelogenic (AML) and acute lymphoblastic leukemias.
• a cancer harbouring activated STAT3 and/or STAT5
• the cancer is from solid or hematological tumors, breast cancer, liver cancer, prostate cancer, blood cancer, skin cancer, head cancer, neck cancer, glioblastoma or acute myelogenic (AML) and acute lymphoblastic leukemias.
• AML acute myelogenic
• FIG. 1 is a graph illustrating a comparative intrinsic clearance rates between AC-3-19 (prior art compound) and compound I;
• Fig. 3B illustrates intrinsic comparative clearance rates between JPX-0369 and compound I
• Fig. 4A illustrates the chemical structure of JPX-0371 (prior art);
• Fig. 4B illustrates intrinsic comparative clearance rates between JPX-0371 and compound I
• Fig. 5 A illustrates the chemical structure of JPX-0318 (prior art)
• Fig. 5B illustrates intrinsic comparative clearance rates between JPX-0318 and compound II.
• Fig. 6 illustrates comparative clearance rates between JPX-0371 and compound I in CD-I mice dosed at 20 mgs/kg (IP).
• Ranges can be expressed herein as from “about” one particular value, and/or to "about” another particular value. When such a range is expressed, a further aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as "about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10" is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
• references in the specification and concluding claims to parts by weight of a particular element or component in a composition denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed.
• X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.
• a weight percent (wt. %) of a component is based on the total weight of the formulation or composition in which the component is included.
• the terms “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
• STAT3 signal transducer and activator of transcription 3 (acute-phase response),” and “signal transducer and activator of transcription 3” can be used interchangeably and refer to a a transcription factor encoded by a gene designated in human as the STAT3 gene, which has a human gene map locus of 17q21 and described by Entrez Gene cytogenetic band: 17q21.31; Ensembl cytogenetic band: 17q21.2; and, HGNC cytogenetic band: 17q21.
• STAT3 refers to a human protein that has 770 amino acids and has a molecular weight of about 88,068 Da.
• the term is inclusive of splice isoforms or variants, and also inclusive of that protein referred to by such alternative designations as: APRF, MGC 16063, Acute-phase response factor, DNA-binding protein APRF, HIES as used by those skilled in the art to that protein encoded by human gene STAT3.
• APRF splice isoforms or variants
• MGC 16063 Acute-phase response factor
• APRF DNA-binding protein
• HIES DNA-binding protein encoded by human gene STAT3.
• the term is also inclusive of the non-human ortholog or homolog thereof.
• STAT5 refers to STAT5A and/or STAT5B. If specific reference to either STAT5A or STAT5B is required, the specific term will be used herein.
• STAT5A and “signal transducer and activator of transcription 5A” can be used interchangeably and refer to a a transcription factor encoded by a gene designated in human as the STAT5A gene, which has a human gene map locus described by Entrez Gene cytogenetic band: 17ql 1.2; Ensembl cytogenetic band: 17q21.2; and, HGNC cytogenetic band: 17q 1 1.2.
• STAT5A refers to a human protein that has 794 amino acids and has a molecular weight of about 90,647 Da.
• the term is inclusive of splice isoforms or variants, and also inclusive of that protein referred to by such alternative designations as MGF and STAT5 as used by those skilled in the art to that protein encoded by human gene STAT5A.
• the term is also inclusive of the non-human ortholog or homolog thereof.
• STAT5B and “signal transducer and activator of transcription 5B” can be used interchangeably and refer to a a transcription factor encoded by a gene designated in human as the STAT5B gene, which has a human gene map locus described by Entrez Gene cytogenetic band: 17ql 1.2; Ensembl cytogenetic band: 17q21.2; and, HGNC cytogenetic band: 17ql 1.2.
• STAT5A refers to a human protein that has 787 amino acids and has a molecular weight of about 89,866 Da.
• the term is inclusive of splice isoforms or variants, and also inclusive of that protein referred to by such alternative designations as transcription factor STAT5B as used by those skilled in the art to that protein encoded by human gene STAT5A.
• the term is also inclusive of the non-human ortholog or homolog thereof.
• the term "subject” can be a vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian.
• the subject of the herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig or rodent. The term does not denote a particular age or sex.
• the subject is a mammal.
• a patient refers herein to a subject afflicted with cancer, preferably glioblastoma.
• patient includes human and veterinary subjects.
• treatment refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder.
• This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder.
• this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
• the term covers any treatment of a subject, including a mammal (e.g., a human), and includes: (i) preventing the disease from occurring in a subject that can be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the disease, i.e., arresting its development; or (iii) relieving the disease, i.e., causing regression of the disease.
• the subject is a mammal such as a primate, and, in a further aspect, the subject is a human.
• subject also includes domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mouse, rabbit, rat, guinea pig, fruit fly, etc.).
• livestock e.g., cattle, horses, pigs, sheep, goats, etc.
• laboratory animals e.g., mouse, rabbit, rat, guinea pig, fruit fly, etc.
• diagnosisd means having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed or treated by the compounds, compositions, or methods disclosed herein.
• diagnosis with a disorder treatable by STAT3 inhibition means having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed or treated by a compound or composition that can inhibit or negatively modulate STAT3.
• diagnosis with a need for inhibition of STAT3 refers to having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition characterized by a dysfunction in STAT3 activity.
• a diagnosis can be in reference to a disorder, such as an oncological disorder or disease, cancer and/or disorder of uncontrolled cellular proliferation and the like, as discussed herein.
• the term "diagnosed with a need for inhibition of STAT3 activity” refers to having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed or treated by inhibition of STAT3 activity.
• diagnosisd with a need for modulation of STAT3 activity means having been subjected to a physical examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed or treated by modulation of STAT3 activity, e.g. negative modulation.
• diagnosisd with a need for treatment of one or more disorder of uncontrolled cellular proliferation associated with STAT3 dysfunction means having been subjected to a physical examination by a person of skill, for example, a physician, and found to have one or disorders of uncontrolled cellular proliferation, e.g. a cancer, associated with STAT3 dysfunction.
• STAT3- or STAT5-dependent cancer refers to a cancer harboring constitutively activated STAT3 or STAT5.
• the phrase "identified to be in need of treatment for a disorder," or the like, refers to selection of a subject based upon need for treatment of the disorder.
• a subject can be identified as having a need for treatment of a disorder (e.g., a disorder related to STAT3 activity) based upon an earlier diagnosis by a person of skill and thereafter subjected to treatment for the disorder.
• the identification can, in one aspect, be performed by a person different from the person making the diagnosis.
• the administration can be performed by one who subsequently performed the administration.
• administering refers to any method of providing a pharmaceutical preparation to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can be continuous or intermittent.
• a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition.
• a preparation can be administered prophylactically; that is, administered for prevention of a disease or condition.
• contacting refers to bringing a disclosed compound and a cell, target STAT3 protein, or other biological entity together in such a manner that the compound can affect the activity of the target (e.g., spliceosome, cell, etc.), either directly; i.e., by interacting with the target itself, or indirectly; i.e., by interacting with another molecule, co factor, factor, or protein on which the activity of the target is dependent.
• the target e.g., spliceosome, cell, etc.
• the terms “effective amount” and “amount effective” refer to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition.
• a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects.
• the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of a compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for purposes of administration.
• compositions can contain such amounts or submultiples thereof to make up the daily dose.
• the dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products.
• a preparation can be administered in a "prophylactically effective amount"; that is, an amount effective for prevention of a disease or condition.
• EC50 is intended to refer to the concentration of a substance (e.g., a compound or a drug) that is required for 50% agonism or activation of a biological process, or component of a process, including a protein, subunit, organelle, ribonucleoprotein, etc.
• a substance e.g., a compound or a drug
• an EC 50 can refer to the concentration of a substance that is required for 50% agonism or activation in vivo , as further defined elsewhere herein.
• EC50 refers to the concentration of agonist or activator that provokes a response halfway between the baseline and maximum response.
• IC 50 is intended to refer to the concentration of a substance (e.g., a compound or a drug) that is required for 50% inhibition of a biological process, or component of a process, including a protein, subunit, organelle, ribonucleoprotein, etc.
• a substance e.g., a compound or a drug
• an IC 50 can refer to the plasma concentration of a substance that is required for 50% inhibition in vivo , as further defined elsewhere herein. More commonly, IC 50 refers to the half maximal (50%) inhibitory concentration (IC) of a substance required to inhibit a process or activity in vitro.
• STAT3 IC 50 refers to the concentration of a substance (e.g., a compound or a drug) that is required for 50% inhibition of a STAT3 activity.
• an IC 50 can refer to the plasma concentration of a substance that is required for 50% inhibition of an in vivo activity or process as further defined elsewhere herein, e.g. tumor growth in an animal or human.
• STAT3 IC50 refers the half maximal (50%) inhibitory concentration (IC) of a substance or compound required to inhibit a process or activity an in vitro context, e.g. a cell-free or cell-based assay.
• the STAT3 IC50 can be in the context of the half-maximal concentration required to inhibit cell growth.
• the response is measured in a cell-line with aberrant STAT3 activity.
• the response is measured in a cell-line with persistently active STAT3.
• the response can be determined using a cell-line derived from a human breast cancer, human pancreatic cancer, and human prostate cancer.
• the response can be measured in a cell-line selected from MDA-MB-231, Panc-1, and DU-145.
• Cell-lines transfected with specific genes can also be used.
• the response can be measured in a cell-line transfected with v-Src.
• the cell-line transfected with v-Src is a permanent cell- line.
• the STAT3 IC 50 is the half-maximal concentration required to inhibit STAT3 activity in a cell-free assay, e.g. an electrophoretic mobility shift assay ("EMSA").
• the STAT3 IC50 is the half-maximal concentration required to inhibit cell- growth, cell viability or cell migration activity.
• STAT3 K D refers to the binding affinity of a compound or substance for the STAT3 determined in an in vitro assay.
• the K D of a substance for a protein can be determined by a variety of methods known to one skilled in the art, e.g. equilibrium dialysis, analytical ultracentrifugation and surface plasmon resonance (“SPR") analysis.
• SPR surface plasmon resonance
• STAT3 K D is defined as the ratio of association and dissociation rate constants determined using SPR analysis using purified STAT3 protein.
• STAT3 K refers to the inhibition constant for the displacement of a STAT3 SH2 probe from STAT3 protein.
• the STAT3 SH2 can be fluorescence-labelled GpYLPQTV.
• the fluorescence label is 5- carboxyfluorescein, although other suitable fluorescence probes can be used as determined to be useful and convenient by one skilled in the art.
• pharmaceutically acceptable describes a material that is not biologically or otherwise undesirable, i.e., without causing an unacceptable level of undesirable biological effects or interacting in a deleterious manner.
• derivative refers to a compound having a structure derived from the structure of a parent compound (e.g., a compound disclosed herein) and whose structure is sufficiently similar to those disclosed herein and based upon that similarity, would be expected by one skilled in the art to exhibit the same or similar activities and utilities as the claimed compounds, or to induce, as a precursor, the same or similar activities and utilities as the claimed compounds.
• exemplary derivatives include salts, esters, amides, salts of esters or amides, and N-oxides of a parent compound.
• aqueous and non-aqueous carriers include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
• Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
• These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
• Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like.
• Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption.
• Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
• the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use.
• Suitable inert carriers can include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.
• a residue of a chemical species refers to the moiety that is the resulting product of the chemical species in a particular reaction scheme or subsequent formulation or chemical product, regardless of whether the moiety is actually obtained from the chemical species.
• the term "substituted" is contemplated to include all permissible substituents of organic compounds.
• the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, and aromatic and nonaromatic substituents of organic compounds.
• Illustrative substituents include, for example, those described below.
• the permissible substituents can be one or more and the same or different for appropriate organic compounds.
• the heteroatoms, such as nitrogen can have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
• substitution or “substituted with” include the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. It is also contemplated that, in certain aspects, unless expressly indicated to the contrary, individual substituents can be further optionally substituted (i.e., further substituted or unsubstituted).
• alkyl as used herein is a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, s-butyl, i- butyl, n-pentyl, isopentyl, i-pentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, dode cyl, tetradecyl, hexadecyl, eicosyl, tetracosyl, and the like.
• alkyl is generally used to refer to both unsubstituted alkyl groups and substituted alkyl groups; however, substituted alkyl groups are also specifically referred to herein by identifying the specific substituent(s) on the alkyl group.
• halogenated alkyl or “haloalkyl” specifically refers to an alkyl group that is substituted with one or more halide, e.g., fluorine, chlorine, bromine, or iodine.
• alkoxy alkyl specifically refers to an alkyl group that is substituted with one or more alkoxy groups, as described below.
• cycloalkyl refers to both unsubstituted and substituted cycloalkyl moieties
• the substituted moieties can, in addition, be specifically identified herein; for example, a particular substituted cycloalkyl can be referred to as, e.g., an "alkylcycloalkyl.”
• a substituted alkoxy can be specifically referred to as, e.g., a "halogenated alkoxy”
• a particular substituted alkenyl can be, e.g., an "alkenylalcohol,” and the like.
• cycloalkyl as used herein is a non-aromatic carbon-based ring composed of at least three carbon atoms.
• examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, and the like.
• heterocycloalkyl is a type of cycloalkyl group as defined above, and is included within the meaning of the term “cycloalkyl,” where at least one of the carbon atoms of the ring is replaced with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
• the cycloalkyl group and heterocycloalkyl group can be substituted or unsubstituted.
• the cycloalkyl group and heterocycloalkyl group can be substituted with one or more groups including, but not limited to, alkyl, cycloalkyl, alkoxy, amino, ether, halide, hydroxy, nitro, silyl, sulfo-oxo, or thiol as described herein.
• polyalkylene group as used herein is a group having two or more CH 2 groups linked to one another.
• the polyalkylene group can be represented by the formula- (CH2) a - , where "a” is an integer of from 2 to 500.
• Alkoxy also includes polymers of alkoxy groups as just described; that is, an alkoxy can be a polyether such as- OA 1 - OA 2 or- OA 1 - (OA 2 ) a - OA 3 , where "a” is an integer of from 1 to 200 and A 1 , A 2 , and A 3 are alkyl and/or cycloalkyl groups.
• alkenyl as used herein is a hydrocarbon group of from 2 to 24 carbon atoms with a structural formula containing at least one carbon-carbon double bond.
• the alkenyl group can be substituted with one or more groups including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol, as described herein.
• groups including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol, as described here
• Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, norbomenyl, and the like.
• heterocycloalkenyl is a type of cycloalkenyl group as defined above, and is included within the meaning of the term “cycloalkenyl,” where at least one of the carbon atoms of the ring is replaced with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
• the cycloalkenyl group and heterocycloalkenyl group can be substituted or unsubstituted.
• alkynyl as used herein is a hydrocarbon group of 2 to 24 carbon atoms with a structural formula containing at least one carbon-carbon triple bond.
• the alkynyl group can be unsubstituted or substituted with one or more groups including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol, as described herein.
• cycloalkynyl as used herein is a non-aromatic carbon-based ring composed of at least seven carbon atoms and containing at least one carbon-carbon triple bound.
• cycloalkynyl groups include, but are not limited to, cycloheptynyl, cyclooctynyl, cyclononynyl, and the like.
• heterocycloalkynyl is a type of cycloalkenyl group as defined above, and is included within the meaning of the term “cycloalkynyl,” where at least one of the carbon atoms of the ring is replaced with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
• the cycloalkynyl group and heterocycloalkynyl group can be substituted or unsubstituted.
• the cycloalkynyl group and heterocycloalkynyl group can be substituted with one or more groups including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol as described herein.
• aryl as used herein is a group that contains any carbon-based aromatic group including, but not limited to, benzene, naphthalene, phenyl, biphenyl, phenoxybenzene, and the like.
• aryl also includes "heteroaryl,” which is defined as a group that contains an aromatic group that has at least one heteroatom incorporated within the ring of the aromatic group. Examples of heteroatoms include, but are not limited to, nitrogen, oxygen, sulfur, and phosphorus.
• non-heteroaryl which is also included in the term “aryl,” defines a group that contains an aromatic group that does not contain a heteroatom. The aryl group can be substituted or unsubstituted.
• the aryl group can be substituted with one or more groups including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol as described herein.
• groups including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, or thiol as described herein.
• amine or “amino” as used herein are represented by the formula- NA A 2 , where A 1 and A 2 can be, independently, hydrogen or alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.
• dialkylamino as used herein is represented by the formula- N(-alkyl)2 where alkyl is a described herein.
• Representative examples include, but are not limited to, dimethylamino group, diethylamino group, dipropylamino group, diisopropylamino group, dibutylamino group, diisobutylamino group, di(sec-butyl)amino group, di(tert-butyl)amino group, dipentylamino group, diisopentylamino group, di(tert-pentyl)amino group, dihexylamino group, N-ethyl-N-methylamino group, N-methyl-N-propylamino group, N- ethyl-N-propylamino group and the like.
• polystyrene resin as used herein is represented by the formula -(A 1 0-(0)C-A 2 -C(0)0) a - or- (A 1 0(0)C-A 2 -0C(0)) a - , where A 1 and A 2 can be, independently, an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group described herein and "a” is an integer from 1 to 500. "Polyester” is as the term used to describe a group that is produced by the reaction between a compound having at least two carboxylic acid groups with a compound having at least two hydroxyl groups.
• ether as used herein is represented by the formula A OA , where A and A can be, independently, an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group described herein.
• polyether as used herein is represented by the formula- (A ⁇ -A ⁇ - , where A 1 and A 2 can be, independently, an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group described herein and "a" is an integer of from 1 to 500.
• polyether groups include polyethylene oxide, polypropylene oxide, and polybutylene oxide.
• halide refers to the halogens fluorine, chlorine, bromine, and iodine.
• heterocycle refers to single and multi-cyclic aromatic or non aromatic ring systems in which at least one of the ring members is other than carbon.
• Heterocycle includes azetidine, dioxane, furan, imidazole, isothiazole, isoxazole, morpholine, oxazole, oxazole, including, 1 ,2,3-oxadiazole, 1,2,5-oxadiazole and 1 ,3,4-oxadiazole, piperazine, piperidine, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, tetrahydrofuran, tetrahydropyran, tetrazine, including 1 ,2,4,5-tetrazine, tetrazole, including 1 ,2,3,4-tetrazole and 1 ,2,4,5-tetrazole, thiadiazole
• hydroxyl as used herein is represented by the formula- OH.
• ketone as used herein is represented by the formula A 1 C(0)A 2 , where A 1 and A 2 can be, independently, an alkyl, cycloaikyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.
• nitrile as used herein is represented by the formula- CN.
• sulfo-oxo as used herein is represented by the formulas- S(0)A 1 ,- S(0) 2 A 1 ,-0S(0) 2 A 1 , or -0S(0) 2 0A 1 , where A 1 can be hydrogen or an alkyl, cycloaikyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.
• sulfonyl is used herein to refer to the sulfo-oxo group represented by the -SlO ⁇ A 1 , where A 1 can be hydrogen or an alkyl, cycloaikyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.
• sulfone as used herein is represented by the formula A 1 S(0) 2 A 2 , where A 1 and A 2 can be, independently, an alkyl, cycloaikyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.
• sulfoxide as used herein is represented by the formula A 1 S(0)A 2 , where A 1 and A 2 can be, independently, an alkyl, cycloaikyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl group as described herein.
• R 1 is a straight chain alkyl group
• one of the hydrogen atoms of the alkyl group can optionally be substituted with a hydroxyl group, an alkoxy group, an alkyl group, a halide, and the like.
• a first group can be incorporated within second group or, alternatively, the first group can be pendant (i.e., attached) to the second group.
• an alkyl group comprising an amino group the amino group can be incorporated within the backbone of the alkyl group.
• the amino group can be attached to the backbone of the alkyl group. The nature of the group(s) that is (are) selected will determine if the first group is embedded or attached to the second group.
• compounds of the invention may contain "optionally substituted" moieties.
• substituted whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
• an "optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
• Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
• individual substituents can be further optionally substituted (i.e., further substituted or unsubstituted).
• stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain aspects, their recovery, purification, and use for one or more of the purposes disclosed herein.
• each R is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently selected from C1.4 aliphatic, -CH 2 Ph, -O(CH 2 ) 0 -iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted” group include: -0(CR * 2 ) 2.3 0-, wherein each independent occurrence of R * is selected from hydrogen, Ci_ 6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6- membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• Suitable substituents on the aliphatic group of R * include halogen, -R * , -(haloR * ), -OH, -OR * , -0(haloR * ), -CN, -C(0)OH, -C(0)OR * , -NH 2 , -NHR * , -NR * 2 , or -N0 2 , wherein each R * is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently C1.4 aliphatic, -CH 2 Ph, -O(CH 2 ) 0 -iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include - R , -NR + 2 , -C(0)R + , -C(0)OR + , -C(0)C(0)R + , -C(0)CH 2 C(0)R + , - S(0) 2 R + , -S(0) 2 NR + 2 , -C(S)NR + 2, -C(NH)NR + 2, or -N(R + )S(0) 2 R + ; wherein each R + is independently hydrogen, Ci_ 6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R + , taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsatur
• Suitable substituents on the aliphatic group of R " are independently halogen, -R ‘ , -(haloR “ ), - OH, -OR ' , -O(haloR ' ), -CN, -C(0)OH, -C(0)OR ' , -NH 2 , -NHR ' , -NR ' 2 , or -N0 2 , wherein each R ' is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently C aliphatic, -CH 2 Ph, -0(CH 2 )o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
• leaving group refers to an atom (or a group of atoms) with electron withdrawing ability that can be displaced as a stable species, taking with it the bonding electrons.
• suitable leaving groups include halides - including chloro, bromo, and iodo - and pseudohalides (sulfonate esters) - including triflate, mesylate, tosylate, and brosylate. It is also contemplated that a hydroxyl moiety can be converted into a leaving group via Mitsunobu reaction.
• hydrolysable group and “hydrolysable moiety” refer to a functional group capable of undergoing hydrolysis, e.g., under basic or acidic conditions.
• hydrolysable residues include, without limitation, acid halides, activated carboxylic acids, and various protecting groups known in the art (see, for example, "Protective Groups in Organic Synthesis,” T. W. Greene, P. G. M. Wuts, Wiley-Interscience, 1999).
• organic residue defines a carbon containing residue, i.e., a residue comprising at least one carbon atom, and includes but is not limited to the carbon-containing groups, residues, or radicals defined hereinabove.
• Organic residues can contain various heteroatoms, or be bonded to another molecule through a heteroatom, including oxygen, nitrogen, sulfur, phosphorus, or the like. Examples of organic residues include but are not limited alkyl or substituted alkyls, alkoxy or substituted alkoxy, mono or di- substituted amino, amide groups, etc.
• Organic residues can preferably comprise 1 to 18 carbon atoms, 1 to 15, carbon atoms, 1 to 12 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms.
• an organic residue can comprise 2 to 18 carbon atoms, 2 to 15, carbon atoms, 2 to 12 carbon atoms, 2 to 8 carbon atoms, 2 to 4 carbon atoms, or 2 to 4 carbon atoms.
• radical refers to a fragment, group, or substructure of a molecule described herein, regardless of how the molecule is prepared.
• the radical for example an alkyl
• substituted alkyl can be further modified (i.e., substituted alkyl) by having bonded thereto one or more "substituent radicals.”
• the number of atoms in a given radical is not critical to the present invention unless it is indicated to the contrary elsewhere herein.
• Organic radicals contain one or more carbon atoms.
• An organic radical can have, for example, 1-26 carbon atoms, 1-18 carbon atoms, 1-12 carbon atoms, 1-8 carbon atoms, 1-6 carbon atoms, or 1-4 carbon atoms.
• an organic radical can have 2-26 carbon atoms, 2-18 carbon atoms, 2-12 carbon atoms, 2-8 carbon atoms, 2-6 carbon atoms, or 2-4 carbon atoms.
• Organic radicals often have hydrogen bound to at least some of the carbon atoms of the organic radical.
• an organic radical can contain 1-10 inorganic heteroatoms bound thereto or therein, including halogens, oxygen, sulfur, nitrogen, phosphorus, and the like.
• organic radicals include but are not limited to an alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, mono-substituted amino, di-substituted amino, acyloxy, cyano, carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, di alkyl carboxamide, substituted dialkylcarboxamide, alkylsulfonyl, alkyl sulfinyl, thioalkyl, thiohaloalkyl, alkoxy, substituted alkoxy, haloalkyl, haloalkoxy, aryl, substituted aryl, heteroaryl, heterocyclic, or substituted heterocyclic radicals, wherein the terms are defined elsewhere herein.
• Inorganic radicals contain no carbon atoms and therefore comprise only atoms other than carbon.
• Inorganic radicals comprise bonded combinations of atoms selected from hydrogen, nitrogen, oxygen, silicon, phosphorus, sulfur, selenium, and halogens such as fluorine, chlorine, bromine, and iodine, which can be present individually or bonded together in their chemically stable combinations.
• Inorganic radicals have 10 or fewer, or preferably one to six or one to four inorganic atoms as listed above bonded together. Examples of inorganic radicals include, but not limited to, amino, hydroxy, halogens, nitro, thiol, sulfate, phosphate, and like commonly known inorganic radicals.
• one of the bonds to the chiral carbon can be depicted as a wedge (bonds to atoms above the plane) and the other can be depicted as a series or wedge of short parallel lines is (bonds to atoms below the plane).
• the Cahn-Inglod-Prelog system can be used to assign the (R) or (S) configuration to a chiral carbon.
• Compounds described herein comprise atoms in both their natural isotopic abundance and in non-natural abundance.
• the disclosed compounds can be isotopically- labelled or isotopically-substituted compounds identical to those described, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature.
• isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 16 0, 17 0, 35 S, 18 F and 36 C1, respectively.
• Compounds further comprise prodrugs thereof and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention.
• Certain isotopically-labelled compounds of the present invention for example those into which radioactive isotopes such as H and C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability.
• Isotopically labelled compounds of the present invention and prodrugs thereof can generally be prepared by carrying out the procedures below, by substituting a readily available isotopically labelled reagent for a non- isotopically labelled reagent.
• ketones with an oc-hydrogen can exist in an equilibrium of the keto form and the enol form.
• keto form enol form amide form imidic acid form Likewise, amides with an N-hydrogen can exist in equilibrium of the amide form and the imidic acid form. Unless stated to the contrary, the invention includes all such possible tautomers.
• a structure of a compound can be represented by a formula:
• n is typically an integer. That is, R n is understood to represent five independent substituents, R n(a) , R n(b) , R n(c) , R n(d) , and R n(e) .
• independent substituents it is meant that each R substituent can be independently defined. For example, if in one instance R n(a) is halogen, then R n(b) is not necessarily halogen in that instance.
• the compounds as defined herein may include a chiral center which gives rise to enantiomers. The compounds may thus exist in the form of two different optical isomers, that is (+) or (-) enantiomers.
• enantiomers and mixtures thereof are included within the scope of the invention.
• the single enantiomer can be obtained by methods well known to those of ordinary skill in the art, such as chiral HPLC, enzymatic resolution and chiral auxiliary derivatization.
• the compounds in accordance with the present disclosure can contain more than one chiral centre.
• the compounds of the present invention may thus exist in the form of different diastereomers. All such diastereomers and mixtures thereof are included within the scope of the invention.
• the single diastereomer can be obtained by methods well known in the art, such as HPLC, crystalisation and chromatography.
• Solvate means that a compound as defined herein incorporates one or more pharmaceutically acceptable solvents including water to give rise to hydrates.
• the solvate may contain one or more molecules of solvent per molecule of compound or may contain one or more molecules of compound per molecule of solvent.
• Illustrative non-limiting examples of hydrates include monohydrate, dihydrate, trihydrate and tetrahydrate or semi-hydrate.
• the solvent may be held in the crystal in various ways and thus, the solvent molecule may occupy lattice positions in the crystal, or they may form bonds with salts of the compounds as described herein.
• the solvate(s) must be "acceptable" in the sense of not being deleterious to the recipient thereof. The solvation may be assessed by methods known in the art such as Loss on Drying techniques (LOD).
• LOD Loss on Drying techniques
• compositions of the invention Disclosed are the components to be used to prepare the compositions of the invention as well as the compositions themselves to be used within the methods disclosed herein.
• these and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds cannot be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular compound is disclosed and discussed and a number of modifications that can be made to a number of molecules including the compounds are discussed, specifically contemplated is each and every combination and permutation of the compound and the modifications that are possible unless specifically indicated to the contrary.
• the invention relates to compounds useful as inhibitors of STAT3/STAT5.
• the disclosed compounds and products of disclosed methods of making are modulators of STAT3/STAT5 activity.
• the present invention relates to compounds that bind to a STAT3 protein and negatively modulate STAT3 activity.
• the present invention relates to compounds that bind to a STAT5 protein and negatively modulate STAT5 activity.
• the disclosed compounds exhibit inhibition of STAT3/5 activity.
• the compounds of the invention are useful in the treatment of cancer associated with STAT3/STAT5 activity dysfunction, such as breast, prostate or brain cancer and glioblastoma, and other diseases in which a STAT3/5 protein is involved, as further described herein.
• each disclosed derivative can be optionally further substituted. It is also contemplated that any one or more derivative can be optionally omitted from the invention. It is understood that a disclosed compound can be provided by the disclosed methods. It is also understood that the disclosed compounds can be employed in the disclosed methods of using.
• a novel series of compounds that exhibit potent anti cancer activity, minimal toxicity in normal cells, exemplary metabolic stability in mouse and human hepatocytes, plasma stability in mice.
• Lead compounds from this series exhibit strong cancer killing potency in acute myeloid leukemia cells, MV4;11 cells with nM IC50S.
• compound I JPX-0431
• compound II JPX-0432
• exhibit ⁇ 6-8-fold greater potency in acute myeloid leukemia cells, MV4;11 than the comparable compound from literature, AC-3-19.
• the exemplary potency and metabolic stability are attributed to a privileged scaffold including compounds of Formula I, which affords protection of the pentafluorobenzenesulfonamide from attack by biological nucleophiles such as glutathione.
• R 2 is a benzyl substituted with 1-5 halogens, preferably -Cl, -F or -Br, and preferably R 2 is selected from:
• R 3 is selected from the group consisting of -H or -OH.
• the compound of Formula I is selected from:
• JPX-313 4-(2-((/V-(4-chlorobenzyl)-2, 3,4,5, 6-pentafluorophenyl)sulfonamido)-/V-(3- cyclopentylbenzyl)acetamido)benzoic acid (JPX-313)
• Compound JPX-313 was prepared according to general procedure d, and was isolated as an amorphous white powder (92%).
• the compounds of this application have unexpected metabolic stability to comparable compounds from literature.
• Anti-cancer efficacy of exemplary compounds of this application was assessed in vitro in different cancer cell lines.
• Cell viability was examined following treatment at various concentration of inhibitor (0.097656-50mM) using a cell Titer-Blue cell viability assay.
• 1X10 4 cells/well were plated in 96-well assay plates in culture medium. All cells were grown in DMEM, IMDM and RPMI-1640 supplemented with 10% FBS. After 24hrs, test compounds and vehicle controls were added to appropriate wells so the final volume was IOOmI in each well. The cells were cultured for the desired test exposure period (72hrs) at 37°C and 5% CO2. The assay plates were removed from 37°C incubator and 20pl/well of CellTiter-Blue® Reagent was added. The plates were incubated using standard cell culture conditions for 1-4 hours and the plates were shaken for 10 seconds and fluorescence recorded at 560/590nm.
• Exemplary compounds of the application showed IC 50 values in the range of 0.4 -8.0 mM, preferably 0.4 - 5.0 pm, against cancer cells, such as MV4-11, MOLM-13, and K562.
• the IC50 values for healthy cells such as MRC9 was typically greater than 20 mM.
• Table 1 presents the IC 50 value of compound I against various cells lines.
• Table 1 IC50 values of compounds as described herein against various cancer and healthy cell lines
• the compounds of this application have unexpected improvements in anti-cancer efficacy over the comparable compounds from literature.
• compound I and compound II have IC 50 ’s of 0.56 and 0.48 mM, respectively, compared to analogous compound, AC-3-19 (described in WO2015179956) which showed significantly lower efficacy with an IC50 ⁇ 3-5 mM.
• Inhibitors were examined in triplicate at a maximal concentration of 50 mM, followed by 1 :2 dilutions in subsequent wells (25, 12.5, 6.25, 3.125, 1.5625, 0.78125, 0.390625, 0.195313 and 0.097656 mM). After 72 h, the wells were treated with CellTiter-Blue® (20 pL/well), and the plates were incubated using standard cell culture conditions for 1 hour. Fluorescence was measured at 560/590 nm. IC 50 values were determined using non-linear regression analysis. Similar procedures were used for the other cell lines.
• a stock of 100 mM test compound was prepared by diluting the 10 mM test compound in DMSO with a solution of 50% acetonitrile and 50% water.
• a solution of 50% acetonitrile and 50% water was prepared in a 96-well non-coated plate, 198 pL of hepatocytes was pipetted, and the plate was placed in the incubator on an orbital shaker to allow the hepatocytes to warm for 10 minutes.
• the aliquots were mixed with a solution of acetonitrile and internal standard (100 nM alprazolam, 200 nM labetalol, and 2 mM ketoprofen) to terminate the reaction.
• the reaction solution was then vortexed for 10 minutes and centrifuged at 4,000 rpm for 30 minutes at 4 °C. 400 mE of the supernatant was transferred to one new 96-well plate, centrifuged at 4,000 rpm for 30 minutes at 4 °C, and 100 mE of the supernatant was transferred to a new 96-well plate ensuring the pellet was not disturbed.
• 100 mE of ultrapure water was added to all samples for analysis by LC-MS/MS.
• the in vitro half-life (Ti /2 ) was determined by the linear regression of the natural logarithm of the remaining percentage of the parent drug vs. incubation time curve. The slope value (k) of the curve was then substituted into the following equation to determine the in vitro half- life
• in vitro intrinsic clearance in vitro CL int , in pL/min/l 0 6 cells was determined by the following equation.
• Bioanalytical method Column - Phenomenex Synergi 4 m Hydro-PR 80A (2.0x30 mm). Mobile phase - 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). Column temperature - room temperature. Injection volumne - 10 mH MS analysis - API 4000 instrument from AB Inc (Canada) with an ESI interface.
• FIG. 6 shows the clearance rate of compounds I and comparative compound, JPX-0371.
• Compound I has a calculated Ti /2 of 3.9 hours, while pentafluorobenzenesulfonamide containing JPX-0371 has a Ti /2 of 0.66 hours.
• the compounds of this application have unexpectedly much slower clearance rates, higher bioavailability than the comparable analogous compounds as shown in Tables 6 and 7 where PK parameters are outline for compound I (Table 6) and JPX-0371 (Table 7). Table 6
• t 1 ⁇ 2 (hr) obtained for compounds JPX-303, JPX-320, JPX-313, and JPX-062 are respectively of 0.35, 0.861, 0.31, and 0.94.
• the amount of a compound of the invention required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition for which treatment is required and the age and condition of the patient and will be ultimately at the discretion of the attendant physician.
• the amount administered will be empirically determined, typically in the range of about lC ⁇ g to 100 mg/kg body weight of the recipient.
• the desired dose may conveniently be presented in a single dose or as divided dose administered at appropriate intervals, for example as two, three, four or more doses per day.
• compositions include, without limitation, those suitable for oral, (including buccal and sub-lingual), transdermal, or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation.
• the formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy.
• the methods for preparing a pharmaceutical composition can include the steps of bringing into association the compound as defined herein and pharmaceutically acceptable excipients and then, if necessary, shaping the product into the desired formulation, including applying a coating when desired.
• Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives.
• the compounds and combinations as defined herein may also be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
• the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
• the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile water or saline, before use.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=71100034

Family Applications (1)

Country Status (6)

Cited By (3)

Citations (2)

Family Cites Families (4)

• 2019
  • 2019-12-20 EP EP19901001.8A patent/EP3898582A4/en not_active Withdrawn
  • 2019-12-20 WO PCT/CA2019/051884 patent/WO2020124262A1/en not_active Ceased
  • 2019-12-20 JP JP2021536402A patent/JP2022515248A/ja active Pending
  • 2019-12-20 CA CA3124267A patent/CA3124267A1/en active Pending
  • 2019-12-20 CN CN201980089744.6A patent/CN113661158A/zh active Pending
  • 2019-12-20 US US17/416,175 patent/US20220089531A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events